thine. Putrescine is further metabolized to spermidine and spermine by S-adenosylmethionine decarboxylase. In mouse 2 To whom correspondence should be addressed Email: sa83161@odin.mdacc.tmc.edu skin the induction of ODC by chemical tumor promoters, and subsequent increases in polyamine levels, has been proposed Targeting specific events associated with tumor developas an obligatory step in tumor promotion (6,7). The correlation ment represents a rational approach to chemoprevention between rapid proliferation and high levels of polyamines in as well as therapeutic intervention. In this study the ability many tissues and tumor types suggested that ODC was likely of difluoromethylornithine (DFMO) to inhibit UV-induced to be an excellent target for chemoprevention. This is supported skin carcinogenesis when administered before or after the by the findings that inhibitors of ODC significantly reduce appearance of tumors was examined. SKH hairless mice skin tumor development in initiation-promotion models (8-were irradiated 3 times per week with 90 mJ/cm 2 ; this 10) and that ODC overexpression is a sufficient condition for dose was increased by 10% weekly to a maximum of 175 tumor promotion (11). Additionally, the observation that in mJ/cm 2 . Mice supplied 0.4% DFMO in the drinking water tumors ODC and polyamine levels are constitutively upcontinuously throughout the experiment had an average of regulated independent of tumor promoter exposure suggests 2.0 tumors/mouse (72% incidence) at 30 weeks while that inhibiting ODC in tumors may also have therapeutic controls had an average of 8.2 tumors/mouse (100% efficacy (12). incidence). DFMO started after 12 weeks of UV, a time D,L-α-Difluoromethylornithine (DFMO) is an analog of prior to tumor appearance, yielded 3.6 tumors and 100%
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ornithine that irreversibly inhibits ODC activity. DFMO is incidence at 30 weeks. Starting DFMO at 22 weeks, when decarboxylated by an enzymatic mechanism that generates an an average of 2.5 tumors were present, caused regression intermediate carbonionic species. With the loss of fluorine this of tumors for several weeks, followed by a slight rebound.
species alkylates a nucleophilic residue near or at the active The final tumor number at 30 weeks was 3.0 (96% site, resulting in covalent binding of the inhibitor to the enzyme incidence). Thus, DFMO has strong chemopreventive (13). This inhibitor has been found to significantly suppress efficacy, as well as therapeutic activity, against UV-induced tumor formation in a number of chemically induced experiskin tumors. Histological and proliferative markers support mental models, including colon and skin (14). this conclusion.
The goal of this study was: (i) to determine whether DFMO has chemopreventive activity against UV-induced skin carcinogenesis; (ii) to determine whether it has therapeutic Introduction activity such that it is efficacious when introduced late in the Recognition that the tumorigenic process occurs by discrete carcinogenic process. While continuous DFMO administration stepwise changes and involves specific quantifiable events was found to have significant preventive activity, administration offers the opportunity of intervening and interfering with these late in the tumor development process was also effective in processes in order to prevent tumor development. Thus, one reducing tumor burden. Thus, DFMO appears to have both of the major approaches to chemoprevention is the use of chemopreventive and therapeutic activity against UV-induced agents known to block specific pathways. While initiation skin cancer. events are generally irreversible, many of the processes associated with promotion and progression can be effectively inhibMaterials and methods ited or reversed, leading to a reduction in tumor incidence and Animal treatment severity (1).
Female hairless SKH:HR-1-hBr mice at 4-6 weeks of age were purchased Chronic exposure to UV radiation is the primary cause of from Charles River Laboratories (Wilmington, MA) and housed 10 per cage. Animals were allowed free access to food (AIN 76A diet) and water and were non-melanoma and melanoma skin cancer in humans. UV housed in climate controlled quarters (22 Ϯ 1°C at 50% humidity) with a 12 light is considered a complete carcinogen in that it has h light/dark cycle. DFMO was provided by the National Cancer Institute, characteristics of both tumor initiators and tumor promoters. Table I , and supplied DFMO either population and changes in their behavior (2, 3) . Tumor promocontinuously or starting at either 12 or 22 weeks after beginning UV irradiation tion events include, but are not limited to, dermal inflammation, and continuing until after termination of the experiment. Irradiation Two days after beginning administration of DFMO, exposure to UV irradiation Abbreviations: BrdU, 5-bromo-2Ј-deoxyuridine; DFMO, D,L-α-difluoromethylornithine; LI, labeling index; ODC, ornithine decarboxylase.
was begun. The UV apparatus consisted of eight Westinghouse FS20 sunlamps, an IL-1400 radiometer and an attached UVB photometer. The spectral Fig. 1 . Chronic DFMO administration has no significant effect on body irradiance for the UV lamps was 280-400 nm, providing 80% UVB and 20% weight. DFMO was administered at a dose of 0.4% in the drinking water. UVA. The peak intensity of the light source was 297 nm. The fluence at 60
Body weights were measured weekly for the duration of the experiment. cm from the dorsal surface of the mice was 0.48-0.50 mJ/cm 2 /s. The mice
The differences in body weights between the control and DFMO groups were placed in individual compartments in an open plastic cage on a rotating were Ͻ10% and not statistically significant. base to abrogate any differences in fluence across the UV light bulbs. Mice were exposed to 90 mJ/cm 2 three times per week; the dose was increased by 10% per week until the dose reached 175 mJ/cm 2 . UV treatment was stopped at 23 weeks. We have previously shown that this protocol produces papillomas and carcinomas between 10 and 20 weeks (15).
Tumor analysis
Tumors were counted weekly and the data expressed both as incidence and as mean number of all tumors per mouse. The diameters of all tumors was measured at the time of death and all tumors were removed, fixed in formalin and processed for microscopic evaluation of tumor type (atypic hyperplasia, papilloma, squamous cell carcinoma or spindle cell carcinoma).
ODC activity
Groups of six mice were placed on DFMO for at least 48 h before a single UV exposure or placed on DFMO for 2 weeks with thrice weekly irradiation. Mice were killed 24 h after the last UV exposure. ODC activity was measured using preparations of epidermis scraped from the backs of irradiated or control animals, as previously described (16). Homogenates of the scrapings were centrifuged and aliquots of the supernatant were incubated at 37°C for 1 h with 0.05 µCi L-[ 14 C]ornithine (52.0 mCi/mmol; Amersham Pharmacia Biotech). Protein content was determined with the Bio-Rad protein assay (Bio-Rad Laboratories, Richmond, CA). 14 CO 2 released from the reaction was trapped in wells containing ethanolamine and counted. The results were calculated as nmol CO 2 /mg protein/h and expressed as a percentage of the control.
Histology and labeling index (LI)
Groups of three or four mice were placed on DFMO for at least 48 h before a single UV exposure or placed on DFMO for 2 weeks with thrice weekly irradiation. Mice were killed 24 and 48 h after the last UV exposure. One hour before death mice were injected i.p. with 2.0% 5-bromo-2Ј-deoxyuridine (BrdU) (Sigma Chemical Co., St Louis, MO) in phosphate-buffered saline at 0.1 mg/g body wt. Sections of exposed skin were removed, fixed in formalin and processed for paraffin embedding. Multiple sections from each mouse were stained with an anti-BrdU antibody (Novocastra Laboratories, Newcastleupon-Tyne, UK) as previously described (17). The antigen-antibody complex was visualized with 3,3Ј-diaminobenzidene (Sigma Chemical Co.) by an Fig. 2 . DFMO inhibits UV-elicited skin tumor development. Using groups avidin-biotin-horseradish peroxidase system (Vectastain Elite ABC kit; Vector of 30 SKH hairless mice, DFMO was administered either continuously Laboratories), linked to affinity-purified biotin-labeled rabbit anti-rat IgG. The throughout the experiment or beginning at either week 12 or 22. UV LI was calculated as the number of cells staining positive for BrdU per mm treatment was stopped at week 23 but DFMO continued until the end of the length of interfollicular basement membrane, using an eyepiece reticule. Three experiment. Tumor incidence was calculated as the percentage of animals 2 cm long sections each from three mice were analyzed.
having tumors in each treatment group (A). Tumors were counted weekly and tumor yield or multiplicity was calculated as the average number of
Results

tumors per mouse for each treatment group (B).
Tumor development All animals were weighed weekly for the duration of the there was a marked difference in tumor incidence between those groups receiving DFMO (continuous DFMO and DFMO experiment. The differences in body weights between the control and DFMO groups were Ͻ10% and not statistically at 12 weeks) and those groups (control and DFMO at 22 weeks) not receiving DFMO. These latter groups reached an significant (Figure 1 ). Final body weights (n ϭ 30, mean Ϯ SD) were 27.6 Ϯ 0.8 (control group), 25.6 Ϯ 0.7 (continuous incidence of~90% at week 21, at which time both the continuous DFMO group and the group in which DFMO was DFMO group), 25.6 Ϯ 0.6 (DFMO at 12 weeks group) and 26.3 Ϯ 1.3 g (DFMO at 22 weeks group).
not started until 12 weeks had an incidence of only 20%. By the termination of the experiment the 12 week DFMO group The tumor data were calculated in terms of incidence (percentage of mice bearing tumors) and multiplicity (average had reached 100% incidence (Figure 2, A) . With regard to tumor multiplicities (Figure 2, B) , up to 23 number of tumors per mouse). Tumors were first observed after 17 weeks of UV irradiation and continued to appear weeks the control and DFMO at 22 weeks groups had similar values (~2.2 tumors/mouse), as would be expected, while at throughout the course of the experiment. Within several weeks ments were carried out. As shown in Figure 4 (A), a single UV treatment caused an~10-fold induction in ODC activity at 24 h. DFMO reduced this activity by Ͼ60%. DFMO administered for 2 weeks (Figure 4, B) , during which time the mice were irradiated six times, reduced UV-induced ODC activity to control levels. ODC activity after six treatments with UV is less than after a single exposure because the skin ODC activity in non-irradiated animals. DFMO was also found to reduce UV-induced increases in keratinocyte proliferation. BrdU labeling was used to calculate that time both DFMO-treated groups had very few tumors (~0.3 tumors/mouse). At termination of the experiment there the LI. As shown in Figure 5 , a single UV treatment raised the LI by 370%. DFMO reduced the UV-induced LI by 33%. were~75% fewer tumors (2.0 tumors/mouse) than in the control group (8.2 tumors/mouse). Starting DFMO administration after More striking, however, was the effect of continuous DFMO administration on chronic (six times) UV irradiation, where 12 weeks of UV reduced tumor multiplicity by 56% (3.6 tumors/mouse). When DFMO was administered at 22 weeks, DFMO reduced the LI to non-irradiated control levels. DFMO alone had no effect on LI. a time at which an average of 2.5 tumors were present, tumor regression was noted for several weeks, such that at week 25 the tumor multiplicity was only 1.0 tumor/mouse. However, Discussion tumor number increased thereafter to a final value of 3.0
The original observations that there is a strong association tumors/mouse (66% inhibition compared with the control between high levels of polyamines and rapid cell proliferation group). The observed tumor regression in the DFMO at 22
were made more than 25 years ago (18-20). The development weeks group was not due to a large decrease in survival in of DFMO by the Merrell Research Institute definitively demonthis group. Between 22 and 25 weeks two mice died in this strated that polyamines derived from ornithine are necessary group; in the DFMO at 12 weeks group four mice died, while for maximum cell growth (21,22). Suppression of polyamine one mouse died in the control group. synthesis, however, generally does not cause the death of At the time of death the diameters of tumors on surviving normal mammalian cells (23,24). An additional observation is mice were measured and recorded. At 30 weeks the percent that polyamine levels are usually elevated in rodent and human surviving mice was 90% in the control group, 97% in the neoplasms, relative to surrounding normal tissue. This has continuous DFMO group and 77% in both the DFMO at 12 been well documented in human and mouse colon and in and 22 weeks groups. For each group tumor size data (Figure mouse epidermis (12, [25] [26] [27] . Because polyamine metabolism 3) were calculated as a percentage of the total (100%). The is believed to be an integral component of the mechanism of administration of continuous DFMO caused a reduction in epithelial carcinogenesis, it was expected that agents that tumor size such that this was the only group having no tumors reduced polyamine synthesis would inhibit tumor development. Ͼ7 mm at the end of the experiment.
Inhibitors of ODC were subsequently shown to suppress Histological analysis of the tumors showed that the majority tumor formation in experimental models of chemically induced of them were papillomas (Table II) . The distribution of tumors bladder, breast, colon and skin cancer (8) (9) (10) (28) (29) (30) . by type (papilloma, squamous cell carcinoma or spindle cell
In this study we have demonstrated that oral DFMO has carcinoma) was not different among the groups except that significant chemopreventive effects on UV-induced skin tumothe DFMO at 12 weeks group had notably fewer squamous rigenesis. Takigawa et al. (8) found that DFMO applied to cell carcinomas and more papillomas. This is in agreement mouse skin or administered in the drinking water (1% w/v) with the tumor size distribution, in that carcinomas are generduring phorbol ester promotion of chemical carcinogen-initially much larger than papillomas in this model. ated mice inhibited the formation of papillomas by 50% and ODC activity and proliferation 90%, respectively. Using a multistage promotion protocol (limited 12-O-tetradecanoylphorbol-13-acetate followed by In order to demonstrate that oral DFMO reduces UV-induced ODC activity in the epidermis, both acute and chronic experimezerein), Weeks et al. (10) found that DFMO was a better Groups of six mice were placed on DFMO for at least 48 h before a single UV (1ϫ UV) exposure or placed on DFMO for 2 weeks with thrice weekly (6ϫ UV) irradiation. Mice were killed 48 h after the last UV exposure; 1 h before death mice were injected i.p. with BrdU. Sections of exposed skin were fixed and processed for immunohistochemical staining for BrdU incorporation. The LI was calculated as the number of cells staining positive for BrdU per mm length of interfollicular basement membrane.
that overexpress ODC in the epidermis, showed that 1% DFMO in the drinking water completely prevented the development of papillomas in carcinogen-treated mice. While concomitant administration of DFMO with exposure to carcinogens/promoters are used to study the prevention of malignant lesions, it has been recognized that this 'preventive' agent may also have therapeutic efficacy. With regard to rodent skin models, using the K14-HPV16 transgenic mice, which develop spontaneous skin lesions, Arbeit et al. (31) showed that treatment with DFMO from 28 to 32 weeks of age, at which time visible lesions were present, caused a marked regression of dysplastic papillomas of the ear and reduced severity of lesions on the chest. Peralta Soler et al. (33) demonstrated that DFMO caused a rapid regression of epidermal papillomas induced by 7,12-dimethylbenz[a]anthracene in transgenic mice overexpressing ODC. In the UV study increase. Whether this represents de novo tumor development, which was occurring in the control group, or the reappearance of regressed tumors due to refractoriness to DFMO is unknown. stage II than stage I inhibitor. Arbeit et al. (31), using K14-HPV16 transgenic mice, which develop spontaneous epidermal Generally, human clinical trials have not shown DFMO alone to be highly efficacious and at doses Ͼ3 g/m 2 /day side effects, cancers, administered DFMO (1% w/v) at distinct stages of neoplastic progression. Those groups receiving DFMO for 32 including hearing loss, occurred (34) (35) (36) . However, recently a re-exploration of DFMO when used in combination with other weeks showed complete inhibition of visible or microscopic malignancies compared with control animals, which had a therapeutic drugs has suggested that this may be a more powerful approach (14). This has been borne out by animal 21% skin cancer incidence. The greater inhibition seen by Arbeit et al. (31) compared with the UV carcinogenesis model studies such as those by Li et al. (37) and Reddy et al. (38) , in which a combination of non-steroidal anti-inflammatory presented here may be due to either the higher dose of DFMO in the Arbeit study (1.0 versus 0.4%) or to differences in the drugs and DFMO acted synergistically to prevent rat colon tumors. 'strength' of the ODC-inducing signals. Our observation that 0.4% DFMO reduced tumor multiplicities by~75% is in
The mechanism of cancer prevention by DFMO, and its therapeutic action, has been suggested to involve more than concordance with an earlier study by Gensler (32) anti-angiogenic effects in vivo (40) . This suppression of 
